While the drugs targeting PD-1 BRAF V600E and RET fusion for pan-cancer treatment is considered as an expansion of the existing drugs for pan-cancer, Vitrakvi® targeting NTRK is a drug truly developed for pan-cancer treatment (Figure 6). This evidence concerns the gene RET and cancer.